Search alternatives:
significant spatial » significant potential (Expand Search), significant negative (Expand Search)
increase decrease » increased release (Expand Search), increased crash (Expand Search)
spatial decrease » spatial release (Expand Search), substantial decrease (Expand Search), small decrease (Expand Search)
significant spatial » significant potential (Expand Search), significant negative (Expand Search)
increase decrease » increased release (Expand Search), increased crash (Expand Search)
spatial decrease » spatial release (Expand Search), substantial decrease (Expand Search), small decrease (Expand Search)
-
1621
-
1622
-
1623
-
1624
-
1625
-
1626
Trends analysis in diabetes mellitus diagnosis according to relative handgrip strength.
Published 2024Subjects: -
1627
-
1628
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
1629
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
1630
Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
1631
-
1632
-
1633
-
1634
-
1635
-
1636
-
1637
-
1638
-
1639
-
1640